Drugs / RS-0139
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04261413 | Dec 2021 → Mar 2026 | cancer | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RS-0139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04261413 ↗ |
| Modality | Other / unclassified | “Tumor Targeted Prodrug RS-0139” NCT04261413 ↗ |